Physician profile
Manuel Arroyo
NPI 1508860412
$2,770.14
in general payments reported to CMS, 2019-2025
27 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $735 · 2020: $347 · 2021: $366 · 2022: $186 · 2023: $405 · 2024: $374 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,136.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $595.72 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $299.55 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $263.32 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $238.24 | 2019-2025 | |
| Lilly USA, LLC | $228.83 | 2020-2025 | Mounjaro, Zepbound |
| Amgen INC. | $184.73 | 2019-2023 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.63 | 2019-2024 | Jardiance, Tradjenta |
| Pfizer INC. | $139.86 | 2019-2025 | |
| Nevro Corp. | $102.31 | 2022 | |
| Janssen Pharmaceuticals, INC | $89.67 | 2019 | |
| Merck Sharp & Dohme LLC | $63.97 | 2019 | |
| Mylan Specialty L.P. | $43.16 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.02 | 2019-2023 | Xifaxan |
| Bioventus LLC | $32.45 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $32.38 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $31.89 | 2019-2020 | |
| Amarin Pharma, INC. | $29.85 | 2019-2020 | |
| Corcept Therapeutics | $25.19 | 2025 | Korlym |
| Vertiflex, INC. | $24.74 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $23.67 | 2023 | Dupixent |
| Ibsa Pharma INC. | $23.08 | 2020 | |
| Sanofi-Aventis U.S. LLC | $17.40 | 2019 | |
| Exact Sciences Corporation | $17.08 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $15.98 | 2024 | Voquezna |
| Dynavax Technologies Corporation | $15.66 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.54 | 2023 | |
| Arbor Pharmaceuticals, INC. | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Arroyo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.